Androgen deprivation therapy is the mainstay treatment of metastatic prostate cancer, achieved mainly by gonadotropin-releasing hormone (GnRH) agonists or antagonists.
To investigate the differential impact of GnRH agonists and antagonists on clinical safety and oncologic outcomes.